Xenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results

Stock News

Mar 09

Xenon Pharmaceuticals (XENE.US) surged more than 42% at Monday's market open, reaching $59.59 per share. The significant move follows the company's announcement on March 9 that its Phase 3 X-TOLE2 study for Azetukalner in treating focal epilepsy successfully met its primary endpoint. Results showed a 53.2% median reduction in seizure frequency for the 25mg dose group, compared to a 10.4% reduction in the placebo group, with a p-value of 0.000000000006. The company confirmed that Azetukalner's safety profile was consistent with earlier studies and demonstrated good tolerability. Xenon Pharmaceuticals also announced plans to submit a New Drug Application for Azetukalner to the U.S. FDA in the third quarter of 2026. In a separate development, William Blair analyst Myles Minter maintained a Buy rating on Xenon Pharmaceuticals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111835642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111835642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111835642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111835642","market":"sg","top_or_hot":-1,"title":"Xenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results","media":"Stock News","content":"<p>Xenon Pharmaceuticals (XENE.US) surged more than 42% at Monday's market open, reaching $59.59 per share. The significant move follows the company's announcement on March 9 that its Phase 3 X-TOLE2 study for Azetukalner in treating focal epilepsy successfully met its primary endpoint. Results showed a 53.2% median reduction in seizure frequency for the 25mg dose group, compared to a 10.4% reduction in the placebo group, with a p-value of 0.000000000006. The company confirmed that Azetukalner's safety profile was consistent with earlier studies and demonstrated good tolerability. Xenon Pharmaceuticals also announced plans to submit a New Drug Application for Azetukalner to the U.S. FDA in the third quarter of 2026. In a separate development, William Blair analyst Myles Minter maintained a Buy rating on Xenon Pharmaceuticals.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenon Pharmaceuticals Soars Over 42% at Opening on Positive Phase 3 Epilepsy Drug Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-09 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xenon Pharmaceuticals (XENE.US) surged more than 42% at Monday's market open, reaching $59.59 per share. The significant move follows the company's announcement on March 9 that its Phase 3 X-TOLE2 study for Azetukalner in treating focal epilepsy successfully met its primary endpoint. Results showed a 53.2% median reduction in seizure frequency for the 25mg dose group, compared to a 10.4% reduction in the placebo group, with a p-value of 0.000000000006. The company confirmed that Azetukalner's safety profile was consistent with earlier studies and demonstrated good tolerability. Xenon Pharmaceuticals also announced plans to submit a New Drug Application for Azetukalner to the U.S. FDA in the third quarter of 2026. In a separate development, William Blair analyst Myles Minter maintained a Buy rating on Xenon Pharmaceuticals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1111835642","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111835642","pubTimestamp":1773065135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Xenon Pharmaceuticals (XENE.US) surged more than 42% at Monday's market open, reaching $59.59 per share. The significant move follows the company's announcement on March 9 that its Phase 3 X-TOLE2...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XENE":"Xenon制药"},"translate_title":"Xenon Pharmaceuticals因3期癫痫药物结果积极而开盘飙升超过42%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":1},"content_text":"Xenon Pharmaceuticals (XENE.US) surged more than 42% at Monday's market open, reaching $59.59 per share. The significant move follows the company's announcement on March 9 that its Phase 3 X-TOLE2 study for Azetukalner in treating focal epilepsy successfully met its primary endpoint. Results showed a 53.2% median reduction in seizure frequency for the 25mg dose group, compared to a 10.4% reduction in the placebo group, with a p-value of 0.000000000006. The company confirmed that Azetukalner's safety profile was consistent with earlier studies and demonstrated good tolerability. Xenon Pharmaceuticals also announced plans to submit a New Drug Application for Azetukalner to the U.S. FDA in the third quarter of 2026. In a separate development, William Blair analyst Myles Minter maintained a Buy rating on Xenon Pharmaceuticals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}